Silo Pharma Inc Total Liabilities
Silo Pharma Inc total liabilities. Based on the latest financial reports, Silo Pharma Inc (SILO) has total liabilities worth $1.07 Million USD as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check SILO financial resilience to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Silo Pharma Inc (2010–2025)
Total liabilities of Silo Pharma Inc from 2010 to 2025. This chart illustrates how Silo Pharma Inc's total liabilities have evolved over time, based on quarterly financial data. Explore Silo Pharma Inc long-term investment allocation to see how much of total assets are deployed in long-term investments.
Silo Pharma Inc Competitors by Total Liabilities
The table below lists competitors of Silo Pharma Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Lasa Supergenerics Limited
NSE:LASA
|
India | Rs152.61 Million |
|
Klondike Silver Corp
V:KS
|
Canada | CA$5.39 Million |
|
Chanson International Holding Class A Ordinary Shares
NASDAQ:CHSN
|
USA | $25.77 Million |
|
AIS Resources Ltd
V:AIS
|
Canada | CA$2.23 Million |
|
Locafy Ltd
NASDAQ:LCFY
|
USA | $1.94 Million |
|
TRU PRECIOUS METALS CORP.
F:706
|
Germany | €1.95 Million |
|
Superior Industries International
NYSE:SUP
|
USA | $756.31 Million |
Liability Composition Analysis (2010–2025)
This chart breaks down Silo Pharma Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see Silo Pharma Inc balance sheet assets.
Liquidity & Leverage Metrics
Silo Pharma Inc Total Liabilities Ratios Explained
Silo Pharma Inc total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 5.36 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.22 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.18 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Silo Pharma Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Silo Pharma Inc (2010–2025)
The table below shows the annual total liabilities of Silo Pharma Inc from 2010 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $1.30 Million | -45.34% |
| 2024-12-31 | $2.38 Million | +51.51% |
| 2023-12-31 | $1.57 Million | +20.52% |
| 2022-12-31 | $1.30 Million | -8.81% |
| 2021-12-31 | $1.43 Million | +878.24% |
| 2020-12-31 | $145.97K | -71.75% |
| 2019-12-31 | $516.74K | +15.35% |
| 2018-12-31 | $447.98K | +2.20% |
| 2017-12-31 | $438.34K | -3.26% |
| 2016-12-31 | $453.10K | -7.67% |
| 2015-12-31 | $490.76K | +21.91% |
| 2014-12-31 | $402.56K | -3.86% |
| 2013-12-31 | $418.72K | +909.61% |
| 2012-12-31 | $41.47K | +1084.94% |
| 2011-12-31 | $3.50K | -107.37% |
| 2010-12-31 | $-47.48K | -- |
About Silo Pharma Inc
Silo Pharma, Inc. operates as a developmental stage biopharmaceutical company. The company is developing therapeutics that address underserved conditions, including post-traumatic stress disorder (PTSD), stress-induced anxiety disorders, fibromyalgia, and central nervous system (CNS) diseases. It focuses on developing traditional therapies and psychedelic treatments in formulations. The company's… Read more